By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162



Company News
Agendia BV Co-Founder Laura van ’t Veer Wins European Cancer Organization Clinical Research Award 1/30/2017 8:48:43 AM
Agendia BV Release: New Data Shows That MammaPrint Substantially Impacts How Breast Cancer Patients In Germany Are Treated 12/21/2016 9:26:54 AM
Agendia BV Release: Three New Studies Presented At San Antonio Breast Cancer Symposium Further Demonstrate Value Of Mammaprint And Blueprint In Individualizing Treatment For Breast Cancer Patients 12/14/2016 7:42:29 AM
Agendia BV’s Mammaprint And Blueprint Tests Highlighted In Multiple Presentations At The 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility 12/2/2016 9:03:18 AM
Agendia BV's Proven Breast Cancer Recurrence Assay, MammaPrint, Now Available In The Middle East 11/8/2016 10:01:23 AM
Agendia BV Announces The Award Of A New Category 1 CPT Code From American Medical Association For The Mammaprint 70-Gene Breast Cancer Recurrence Assay 11/2/2016 8:52:46 AM
Agendia BV Expands Its Business Activities In Germany 10/26/2016 9:08:30 AM
Agendia BV Appoints Three Leading Cancer Physicians To Its Medical Advisory Board 10/17/2016 12:04:22 PM
Agendia BV Release: The New England Journal of Medicine Publishes MINDACT Trial Results Proving The Clinical Utility Of Mammaprint In Assisting Physicians To Identify Early-Stage Breast Cancer Patients Who Can Safely Forgo Chemotherapy 8/25/2016 8:49:21 AM
Agendia BV’s Mammaprint First And Only Genomic Assay To Receive Level 1A Clinical Utility Evidence For Chemotherapy Benefit In Early Breast Cancer Patients 4/19/2016 10:52:22 AM